Jules Bordet Institute

• NCT07143279

  Early phase 1, Recruiting, 20 people, 27 Aug 2025

• NCT04954599

  Collaborator, Phase 1/2, Recruiting, 126 people, 8 Jul 2021

• NCT04551495

  Phase 2, Status unknown, 65 people, 16 Sept 2020

• NCT04019548

  Phase 3, Recruiting, 110 people, 15 Jul 2019

• Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

  Phase 1/2, Active, not recruiting, 129 people, 6 Aug 2018

• NCT03498716

  Collaborator, Phase 3, Terminated, 2,199 people, 17 Apr 2018

• NCT03409198

  Collaborator, Phase 2, Completed, 82 people, 24 Jan 2018

• NCT03339843

  Phase 2, Completed, 85 people, 13 Nov 2017

• NCT03307941

  Phase 1/2, Withdrawn, 0 people, 12 Oct 2017

• NCT03065621

  Phase 2, Completed, 100 people, 28 Feb 2017

• NCT02958163

  Collaborator, Phase 2, Terminated, 3 people, 8 Nov 2016

• NCT02053597

  Phase 2, Withdrawn, 0 people, 3 Feb 2014

• NCT02028364

  Phase 2, Completed, 55 people, 7 Jan 2014

• NCT01864798

  Phase 2, Terminated, 27 people, 30 May 2013

• NCT01481701

  Phase 2, Completed, 90 people, 29 Nov 2011

• NCT01428973

  Collaborator, Phase 2, Status unknown, 200 people, 5 Sept 2011

• NCT01045382

  Collaborator, Phase 2, Terminated, 39 people, 11 Jan 2010

• NCT00199134

  Phase 2, Completed, 49 people, 20 Sept 2005

Sources: clinicaltrials.gov